Collaborative Technologies, Inc. – Trademark Portfolio
Entity Type: 03
Collaborative Technologies, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EQUISTAT and MARIPONICS. The owner is based in Stony Brook, NY.
50 East Loop Road
Stony Brook, NY 11790
Showing of trademarks Trademarks
Trademark Classifications
Collaborative Technologies, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Collaborative Technologies, Inc. have?
Collaborative Technologies, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 abandoned, 1 cancelled.
What trademark classes does Collaborative Technologies, Inc. file in?
Collaborative Technologies, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Collaborative Technologies, Inc.'s most well-known trademarks?
Collaborative Technologies, Inc.'s registered trademark portfolio includes well-known marks such as EQUISTAT and MARIPONICS. These are among 2 currently registered trademarks in the portfolio.
What is Collaborative Technologies, Inc.'s trademark registration success rate?
Collaborative Technologies, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.